id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-1996-N-0006-0067,FDA,FDA-1996-N-0006,"Letter from FDA/CDER Division of Nonprescription Regulation Development to Keller and Heckman, LLP, May 4, 2009",Other,Letter(s),2009-05-05T04:00:00Z,2009,5,2009-05-05T04:00:00Z,,2015-05-05T18:56:47Z,,0,0,0900006480975db3
FDA-1996-N-0006-0076,FDA,FDA-1996-N-0006,"Letter from FDA/CDER Division of Nonprescription Regulation Development to Buchanan Ingersoll, May 4, 2009",Other,Letter(s),2009-05-05T04:00:00Z,2009,5,2009-05-05T04:00:00Z,,2015-05-05T19:26:22Z,,0,0,090000648097603e
FDA-1996-N-0006-0070,FDA,FDA-1996-N-0006,"Letter from FDA/CDER Division of Nonprescription Regulation Development to Morgan, Lewis & Bockius, LLP, May 4, 2009",Other,Letter(s),2009-05-05T04:00:00Z,2009,5,2009-05-05T04:00:00Z,,2015-05-05T19:09:46Z,,0,0,0900006480976038
FDA-1996-N-0006-0065,FDA,FDA-1996-N-0006,"Letter from FDA/CDER Division of Nonprescription Regulation Development to Steinberg & Associates, Inc., May 4, 2009",Other,Letter(s),2009-05-05T04:00:00Z,2009,5,2009-05-05T04:00:00Z,,2015-05-05T18:48:08Z,,0,0,0900006480975db0
FDA-1996-N-0006-0068,FDA,FDA-1996-N-0006,"Letter from FDA/CDER Division of Nonprescription Regulation Development to The Personal Care Products Council, May 4, 2009",Other,Letter(s),2009-05-05T04:00:00Z,2009,5,2009-05-05T04:00:00Z,,2015-05-05T18:59:39Z,,0,0,0900006480975db4
FDA-1996-N-0006-0075,FDA,FDA-1996-N-0006,"Letter From FDA/CDER Division of Nonprescription Regulation Development to Dow Pharmaceutical Sciences, May 4, 2009",Other,Letter(s),2009-05-05T04:00:00Z,2009,5,2009-05-05T04:00:00Z,,2015-05-05T19:24:17Z,,0,0,090000648097603d
FDA-1996-N-0006-0077,FDA,FDA-1996-N-0006,"Letter from FDA/CDER Division of Nonprescription Regulation Development to RJR Consulting, Inc., May 4, 2009",Other,Letter(s),2009-05-05T04:00:00Z,2009,5,2009-05-05T04:00:00Z,,2015-05-05T19:28:13Z,,0,0,090000648097603f
FDA-1996-N-0006-0071,FDA,FDA-1996-N-0006,"Letter from FDA/CDER Division of Nonprescription Regulation Development to 3V, Inc., May 4, 2009",Other,Letter(s),2009-05-05T04:00:00Z,2009,5,2009-05-05T04:00:00Z,,2015-05-05T19:13:03Z,,0,0,0900006480976039
FDA-1996-N-0006-0072,FDA,FDA-1996-N-0006,"Letter from FDA/CDER Division of Nonprescription Regulation Development to CIBA Specialty Chemicals Corporation, May 4, 2009",Other,Letter(s),2009-05-05T04:00:00Z,2009,5,2009-05-05T04:00:00Z,,2015-05-05T19:16:57Z,,0,0,090000648097603a
FDA-1996-N-0006-0069,FDA,FDA-1996-N-0006,"Letter from FDA/CDER Division of Nonprescription Regulation Development to L'Oreal USA Products R&D, May 4, 2009",Other,Letter(s),2009-05-05T04:00:00Z,2009,5,2009-05-05T04:00:00Z,,2015-05-05T19:05:01Z,,0,0,0900006480976037
FDA-1996-N-0006-0073,FDA,FDA-1996-N-0006,"Letter from FDA/CDER Division of Nonprescription Regulation Development to Consumer Healthcare Products Association (CHPA), May 4, 2009",Other,Letter(s),2009-05-05T04:00:00Z,2009,5,2009-05-05T04:00:00Z,,2015-05-05T19:20:57Z,,0,0,090000648097603b
FDA-1996-N-0006-0066,FDA,FDA-1996-N-0006,"Letter from FDA/CDER Division of Nonprescription Regulation Development to Ropes & Gray, LLP, May 4, 2009",Other,Letter(s),2009-05-05T04:00:00Z,2009,5,2009-05-05T04:00:00Z,,2015-05-05T18:53:34Z,,0,0,0900006480975db2
FDA-1996-N-0006-0074,FDA,FDA-1996-N-0006,"Letter from FDA/CDER Division of Nonprescription Regulation Development to Parexel International, May 4, 2009",Other,Letter(s),2009-05-05T04:00:00Z,2009,5,2009-05-05T04:00:00Z,,2015-05-05T19:22:46Z,,0,0,090000648097603c
FDA-1996-N-0006-0058,FDA,FDA-1996-N-0006,"Letter from FDA/CDER Division of Nonprescription Regulation Development to Morgan, Lewis & Bockius, LLP",Other,Letter(s),2009-04-16T04:00:00Z,2009,4,2009-04-16T04:00:00Z,,2015-05-05T18:41:16Z,,0,0,090000648095735a
FDA-1996-N-0006-0055,FDA,FDA-1996-N-0006,Letter from FDA/CDER Division of Nonprescription Regulation Development to CIBA Specialty Chemicals Corporation,Other,Letter(s),2009-04-16T04:00:00Z,2009,4,2009-04-16T04:00:00Z,,2015-05-05T18:36:15Z,,0,0,090000648095725e
FDA-1996-N-0006-0056,FDA,FDA-1996-N-0006,Letter from FDA/CDER Division of Nonprescription Regulation Development to Buchanan Ingersoll,Other,Letter(s),2009-04-16T04:00:00Z,2009,4,2009-04-16T04:00:00Z,,2015-05-05T18:38:09Z,,0,0,0900006480957293
FDA-1996-N-0006-0052,FDA,FDA-1996-N-0006,"Letter from FDA/CDER Division of Nonprescription Regulation Development to 3V, Inc.",Other,Letter(s),2009-04-16T04:00:00Z,2009,4,2009-04-16T04:00:00Z,,2015-05-05T18:30:48Z,,0,0,09000064809571c2
FDA-1996-N-0006-0062,FDA,FDA-1996-N-0006,"Letter from Steinberg & Associates, Inc. to FDA/CDER Questions",Other,Letter(s),2009-04-16T04:00:00Z,2009,4,2009-04-16T04:00:00Z,,2015-05-05T18:03:20Z,,0,0,0900006480957545
FDA-1996-N-0006-0051,FDA,FDA-1996-N-0006,Letter from FDA/CDER Division of Nonprescription Regulation Development to Parexel International,Other,Letter(s),2009-04-16T04:00:00Z,2009,4,2009-04-16T04:00:00Z,,2015-05-05T18:28:40Z,,0,0,0900006480957156
FDA-1996-N-0006-0049,FDA,FDA-1996-N-0006,Letter from FDA/CDER Division of Nonprescription Regulation Development to The Personal Care Products Council,Other,Letter(s),2009-04-16T04:00:00Z,2009,4,2009-04-16T04:00:00Z,,2015-05-05T18:24:11Z,,0,0,0900006480956ede
FDA-1996-N-0006-0061,FDA,FDA-1996-N-0006,"Letter from FDA/CDER Division of Nonprescription Regulation Development to Steinberg & Associates, Inc.",Other,Letter(s),2009-04-16T04:00:00Z,2009,4,2009-04-16T04:00:00Z,,2015-05-05T18:46:23Z,,0,0,090000648095744d
FDA-1996-N-0006-0053,FDA,FDA-1996-N-0006,Letter from FDA/CDER Division of Nonprescription Regulation Development to Dow Pharmaceutical Sciences,Other,Letter(s),2009-04-16T04:00:00Z,2009,4,2009-04-16T04:00:00Z,,2015-05-05T18:32:36Z,,0,0,0900006480957206
FDA-1996-N-0006-0059,FDA,FDA-1996-N-0006,"Letter from FDA/CDER Division of Nonprescription Regulation Development to Ropes & Gray, LLP",Other,Letter(s),2009-04-16T04:00:00Z,2009,4,2009-04-16T04:00:00Z,,2015-05-05T18:43:16Z,,0,0,09000064809573e1
FDA-1996-N-0006-0057,FDA,FDA-1996-N-0006,Letter from FDA/CDER Division of Nonprescription Regulation Development to L'Oreal USA Products R&D,Other,Letter(s),2009-04-16T04:00:00Z,2009,4,2009-04-16T04:00:00Z,,2015-05-05T18:39:36Z,,0,0,09000064809572ff
FDA-1996-N-0006-0050,FDA,FDA-1996-N-0006,"Letter from FDA/CDER Division of Nonprescription Regulation Development to RJR Consulting, Inc.",Other,Letter(s),2009-04-16T04:00:00Z,2009,4,2009-04-16T04:00:00Z,,2015-05-05T18:26:52Z,,0,0,0900006480956f1d
FDA-1996-N-0006-0054,FDA,FDA-1996-N-0006,"Letter from FDA/CDER Division of Nonprescription Regulation Development to Keller and Heckman, LLP",Other,Letter(s),2009-04-16T04:00:00Z,2009,4,2009-04-16T04:00:00Z,,2015-05-05T18:34:24Z,,0,0,0900006480957233
FDA-1996-N-0006-0060,FDA,FDA-1996-N-0006,Letter from FDA/CDER Division of Nonprescription Regulation Development to Consumer Healthcare Products Association (CHPA),Other,Letter(s),2009-04-16T04:00:00Z,2009,4,2009-04-16T04:00:00Z,,2015-05-05T18:44:54Z,,0,0,0900006480957423
FDA-1996-N-0006-0048,FDA,FDA-1996-N-0006,Letter from FDA/CDER Additional Conditions in the Over-the-Counter Drug Monograph System - Time and Extent Application (TEA) Process; Request for Information and Questions; Extension of Deadline for Submissions,Other,Letter(s),2009-04-16T04:00:00Z,2009,4,2009-04-16T04:00:00Z,2009-05-01T03:59:59Z,2015-05-05T18:21:11Z,,0,0,0900006480954d7f
FDA-1996-N-0006-0041,FDA,FDA-1996-N-0006,"Letter from FDA/CDER Division of Nonprescription Regulation Development to Ropes & Gray, LLP",Other,Letter(s),2009-04-14T04:00:00Z,2009,4,2009-04-14T04:00:00Z,,2015-05-05T15:50:55Z,,0,0,0900006480953826
FDA-1996-N-0006-0040,FDA,FDA-1996-N-0006,"Letter from FDA/CDER Division of Nonprescription Regulation Development to Morgan, Lewis & Bockius, LLP",Other,Letter(s),2009-04-14T04:00:00Z,2009,4,2009-04-14T04:00:00Z,,2015-05-05T14:31:23Z,,0,0,090000648095381d
FDA-1996-N-0006-0028,FDA,FDA-1996-N-0006,Letter from FDA/CDER Additional Conditions in the Over-the-Counter Drug Monograph System - Time and Extent Application (TEA) Process; Request for Information and Questions,Other,Letter(s),2009-04-14T04:00:00Z,2009,4,2009-03-25T04:00:00Z,2009-04-16T03:59:59Z,2015-03-21T23:15:06Z,,0,0,0900006480953243
FDA-1996-N-0006-0030,FDA,FDA-1996-N-0006,"Letter from FDA/CDER Division of Nonprescription Regulation Development to RJR Consulting, Inc.",Other,Letter(s),2009-04-14T04:00:00Z,2009,4,2009-04-14T04:00:00Z,,2015-03-23T14:50:02Z,,0,0,0900006480953663
FDA-1996-N-0006-0038,FDA,FDA-1996-N-0006,"Letter from FDA/CDER Division of Nonprescription Regulation Development to Sue Ismiel & Daughters US, Inc",Other,Letter(s),2009-04-14T04:00:00Z,2009,4,2009-04-14T04:00:00Z,,2015-06-25T17:02:09Z,,0,0,0900006480953801
FDA-1996-N-0006-0045,FDA,FDA-1996-N-0006,Letter from Ciba Corporation to FDA/CDER Questions,Other,Letter(s),2009-04-14T04:00:00Z,2009,4,2009-04-14T04:00:00Z,,2015-05-05T18:00:11Z,,0,0,0900006480953612
FDA-1996-N-0006-0029,FDA,FDA-1996-N-0006,Letter from FDA/CDER Division of Nonprescription Regulation Development to The Personal Care Products Council,Other,Letter(s),2009-04-14T04:00:00Z,2009,4,2009-04-14T04:00:00Z,,2015-03-23T14:41:34Z,,0,0,0900006480953641
FDA-1996-N-0006-0031,FDA,FDA-1996-N-0006,Letter from FDA/CDER Division of Nonprescription Regulation Development to Parexel International,Other,Letter(s),2009-04-14T04:00:00Z,2009,4,2009-04-14T04:00:00Z,,2015-05-05T13:57:13Z,,0,0,090000648095377d
FDA-1996-N-0006-0042,FDA,FDA-1996-N-0006,Letter from FDA/CDER Division of Nonprescription Regulation Development to Consumer Healthcare Products Association (CHPA),Other,Letter(s),2009-04-14T04:00:00Z,2009,4,2009-04-14T04:00:00Z,,2015-05-05T17:58:25Z,,0,0,0900006480953851
FDA-1996-N-0006-0037,FDA,FDA-1996-N-0006,Letter from FDA/CDER Division of Nonprescription Regulation Development to Symrise,Other,Letter(s),2009-04-14T04:00:00Z,2009,4,2009-04-14T04:00:00Z,,2015-05-05T14:14:40Z,,0,0,09000064809537f3
FDA-1996-N-0006-0039,FDA,FDA-1996-N-0006,Letter from FDA/CDER Division of Nonprescription Regulation Development to L'Oreal USA Products R&D,Other,Letter(s),2009-04-14T04:00:00Z,2009,4,2009-04-14T04:00:00Z,,2015-06-25T17:03:14Z,,0,0,090000648095380f
FDA-1996-N-0006-0046,FDA,FDA-1996-N-0006,Letter from Consumer Healthcare Products Association (CHPA) to FDA/CDER Questions,Other,Letter(s),2009-04-14T04:00:00Z,2009,4,2009-04-14T04:00:00Z,,2015-05-05T18:01:50Z,,0,0,090000648095293d
FDA-1996-N-0006-0032,FDA,FDA-1996-N-0006,"Letter from FDA/CDER Division of Nonprescription Regulation Development to 3V, Inc.",Other,Letter(s),2009-04-14T04:00:00Z,2009,4,2009-04-14T04:00:00Z,,2015-05-05T13:57:36Z,,0,0,09000064809537a4
FDA-1996-N-0006-0047,FDA,FDA-1996-N-0006,"Letter from Morgan, Lewis & Bockius, LLP to FDA/CDER Questions",Other,Letter(s),2009-04-14T04:00:00Z,2009,4,2009-04-14T04:00:00Z,,2015-03-20T19:24:24Z,,0,0,09000064809538ba
FDA-1996-N-0006-0043,FDA,FDA-1996-N-0006,"Letter from 3V, Inc.",Other,Letter(s),2009-04-14T04:00:00Z,2009,4,2009-04-14T04:00:00Z,,2015-05-05T17:59:31Z,,0,0,090000648095375c
FDA-1996-N-0006-0033,FDA,FDA-1996-N-0006,Letter from FDA/CDER Division of Nonprescription Regulation Development to Dow Pharmaceutical Sciences Inc.,Other,Letter(s),2009-04-14T04:00:00Z,2009,4,2009-04-14T04:00:00Z,,2015-05-05T13:57:59Z,,0,0,09000064809537b5
FDA-1996-N-0006-0036,FDA,FDA-1996-N-0006,Letter from FDA/CDER Division of Nonprescription Regulation Development to Buchanan Ingersoll,Other,Letter(s),2009-04-14T04:00:00Z,2009,4,2009-04-14T04:00:00Z,,2015-05-05T14:11:35Z,,0,0,09000064809537e4
FDA-1996-N-0006-0034,FDA,FDA-1996-N-0006,"Letter from FDA/CDER Division of Nonprescription Regulation Development to Keller and Heckman, LLP",Other,Letter(s),2009-04-14T04:00:00Z,2009,4,2009-04-14T04:00:00Z,,2015-05-05T14:01:18Z,,0,0,09000064809537c8
FDA-1996-N-0006-0035,FDA,FDA-1996-N-0006,Letter from FDA/CDER Division of Nonprescription Regulation Development to CIBA Specialty Chemicals Corporation,Other,Letter(s),2009-04-14T04:00:00Z,2009,4,2009-04-14T04:00:00Z,,2015-05-05T14:09:14Z,,0,0,09000064809537d6
FDA-1996-N-0006-0044,FDA,FDA-1996-N-0006,See FDA-1996-N-0006-0062,Supporting & Related Material,,2009-04-14T00:00:00Z,2009,4,,,2009-04-17T04:08:16Z,,0,1,09000064809535ba